Overview of Dr. Inzucchi
Dr. Silvio Inzucchi is an endocrinologist in New Haven, CT and is affiliated with Yale-New Haven Hospital. He received his medical degree from Harvard Medical School and has been in practice 32 years. Dr. Inzucchi accepts several types of health insurance, listed below. He is one of 58 doctors at Yale-New Haven Hospital who specialize in Endocrinology. He has more than 100 publications and over 500 citings.
Office
789 Howard Avenue 2nd Floor
Dana Building
New Haven, CT 06510
Education & Training
- Yale-New Haven Medical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 1992 - 1994
- Yale-New Haven Medical CenterResidency, Internal Medicine, 1985 - 1987
- Harvard Medical SchoolClass of 1985
Certifications & Licensure
- CT State Medical License 1987 - 2025
- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2008-2014
- New York Magazine: Top Doctors Castle Connolly, 2007-2014
- Top Doctors: New York Metro Area Castle Connolly, 2006-2014
- Join now to see all
Publications & Presentations
PubMed
- 24 citationsUse of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA-REG OUTCOME trialPierpaolo Pellicori, David Fitchett, Mikhail Kosiborod, Anne Pernille Ofstad, Leo Seman
European Journal of Heart Failure. 2021-06-28 - 15 citationsPatient Characteristics, Clinical Outcomes, and Effect of Dapagliflozin in Relation to Duration of Heart Failure: Is It Ever Too Late to Start a New Therapy?Su E. Yeoh, Pooja Dewan, Pardeep S. Jhund, Silvio E. Inzucchi, Lars Køber
Circulation. Heart Failure. 2020-11-09 - 66 citationsEfficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial.Michael Böhm, Jonathan Slawik, Martina Brueckmann, Michaela Mattheus, Jyothis T. George
European Journal of Heart Failure. 2020-01-01
Journal Articles
- Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME TrialSilvio Inzucchi, MD, Journal of the American Society of Nephrology
- Cardiovascular Safety of Lorcaserin in Overweight or Obese PatientsErin A Bohula, Stephen D Wiviott, Benjamin M Scirica, Darren K McGuire, Marc S Sabatine, Marc P Bonaca, Christian T Ruff, Silvio E Inzucchi, The New England Journal of Medicine
- Cardiovascular Safety of Lorcaserin in Overweight or Obese PatientsChristina L. Fanola, Darren K. McGuire, Silvio E. Inzucchi, Erin A. Bohula, The New England Journal of Medicine
Lectures
- Reduction in Albuminuria with Dapagliflozin Cannot Be Predicted by Baseline Clinical Characteristics or Changes in Most Other Risk MarkersAmerican Heart Association, Scientific Sessions 2010, Chicago, Illinois, USA
- Reduction in Albuminuria with Dapagliflozin Cannot Be Predicted by Baseline Clinical Characteristics or Changes in Most Other Risk MarkersScientific Sessions 2008, New Orleans, Louisiana, USA
- Reduction in Albuminuria with Dapagliflozin Cannot Be Predicted by Baseline Clinical Characteristics or Changes in Most Other Risk MarkersScientific Sessions 2010, Chicago, Illinois, USA
- Join now to see all
Other
- Reduction in Albuminuria with Dapagliflozin Cannot Be Predicted by Baseline Clinical Characteristics or Changes in Most Other Risk MarkersSilvio Inzucchi, MD, Diabetes, Obesity and Metabolism
https://www.doximity.com/articles/b552b1a0-ea89-475a-8388-913374468095
UpToDate, Wolters Kluwer Health - 2012-07-30 - Oral Pharmacologic Treatment of Type 2 Diabetes MellitusSilvio Inzucchi, MD, Annals of Internal Medicine
https://www.doximity.com/articles/dea6d159-a396-4c8a-8d46-4b009fecfb26
UpToDate, Wolters Kluwer Health - 2012-05-24
Press Mentions
- SGLT2 Inhibitors Cut AFib Risk in Real-Word AnalysisJune 13th, 2022
- SGLT2 Inhibitors Cut AFib Risk in Real-Word AnalysisJune 13th, 2022
- Explaining Insulin Resistance, and How to Reverse ItOctober 25th, 2021
- Join now to see all
Grant Support
- GRADE TrialNIDDK2013–2020
- IRIS TrialNINDS2004–2016
- Dosage According To IGF1 Response In Growth Hormone DefiNational Center For Research Resources2000–2001
- Effects Of Troglitazone And Metformin On Glucose MetabolismNational Center For Research Resources1996–1999
- Ovine CRH In Evaluation Of Cushing SyndromeNational Center For Research Resources1997
- Endocrine Evaluation Of Patients With Diseases Of The PituitaryNational Center For Research Resources1996–1997
- Effects Of Growth Hormone Replacement In GH Deficient AdultsNational Center For Research Resources1996
Professional Memberships
- Member
- Member
- Member
- Member
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
Anthem Blue Access PPO
Anthem Blue Preferred HMO
Anthem Blue Preferred Plus POS
BCBS Blue Card PPO
BCBS Illinois PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Cofinity PPO
Connecticare FlexPOSFirst Health PPO
GHI PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
Oxford Health Freedom
Oxford Health Liberty
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
WEA Trust POS-SE
WEA Trust Preferred Provider Plan - Trust Pref - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: